Nova Patents
EP1925303A2

Use of Angiotensin II type 1 receptor antagonists for the prevention of diabetes

Abstract

The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof, particularly ramipril or ramiprilat, in the manufacture of a medicament for the prevention of stroke, diabetes and /or congestive heart failure (CHF). The present invention further relates to a method of prevention and/or treatment of stroke, diabetes and/or CHF, comprising administering a therapeutically effective amount of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof, particularly ramipril or ramiprilat, to a patient in need of such prevention and/or treatment.

Term

Term ended

Projected expiry passed 25 August 2020, 6.1 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

20 claims: 11 independent, 9 dependent

  1. 1
    The use of an angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention of stroke.
  2. 2
    The use of an angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention of stroke in patients exhibiting normal or low blood pressure.
  3. 3
    The use of an angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention of diabetes.
  4. 4
    The use of an inhibitor angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention of development of congestive heart failure (CHF) in patients with no preexisting CHF.
  5. 7
    A method of prevention of stroke, comprising administering a therapeutically effective amount of an angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof, to a patient in need of such prevention.
  6. 8
    The method of prevention of stroke in patients exhibiting normal or low blood pressure, comprising administering a therapeutically effective amount of an angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof, to a patient in need of such prevention.
  7. 9
    The method of prevention of diabetes, comprising administering a therapeutically effective amount of an angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof, to a patient in need of such prevention.
  8. 10
    The method of prevention of development of CHF in patients with no preexisting CHF, comprising administering a therapeutically effective amount of angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof, to a patient in need of such prevention.
  9. 11
    The method of prevention according to any one of claims 7-10, wherein the AT II antagonist or a pharmaceutically acceptable salt thereof is selected from the group consisting of candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan.
  10. 13
    A pharmaceutical formulation for use in the prevention of stroke, diabetes and/or CHF, comprising a therapeutically effective amount of angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof.
  11. 18
    The use of an angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof, in the prevention of stroke, diabetes and/or CHF, by administering the angiotensin II type 1 receptor (AT II) antagonist or a pharmaceutically acceptable salt thereof, to a patient in need of such prevention.
Independent claims11